The Importance of Pre-Use Integrity Testing in Sterilizing Filtration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Pre-use integrity testing of sterilizing-grade filters eliminates the potential adverse effects of filter loading on the integrity-test results, allowing unambiguous correlation with the integrity-test specification established during filter-validation studies.


Pharmaceutical Technology


It has been shown that hydrodynamic flow is preferentially directed to the larger pores in a filter membrane (4). This means that hydrodynamic flow directs the suspended particles to the largest pores. However, because the largest pores are far less numerous than the average-sized pores, particles initially tend to be captured by the many smaller pores. As the smaller pores become blocked, the hydrodynamic flow directs more of the particles to the larger pores. The larger pores now may become blocked or partially blocked because of bridging, which is promoted by high levels of particulates competing for the pore openings. This phenomenon is corroborated by Grant and Zahka (5). They showed that during the filtration of a dilute suspension of silica particles there was complete retention at the beginning of the filtration, followed by particle passage. The retention then increased as the filtration continued. Similar results were obtained by Roberts and Velazquez while filtering latex particles (6). Thomas et al. found that the successive changes affecting a filter's pore-size distribution as a filtration of Pseudomonas aeruginosa progressed showed the larger pores to be less immediately engaged in the retention of particles (7).

Effect of filter loading on integrity-test results

The effects of filter loading on diffusive flow and the bubble point have been evaluated; however, comprehensive studies remain to be performed, and understanding of these effects is currently incomplete. Trotter et al. showed that the diffusive-flow values at 45 psi began to change at a bacterial cell loading of 1 × 102, while the bubble point remained essentially unchanged until the bacterial cell loading approached 1 x 108 (8).

Particle capture inherently reduces the porosity of the filter, thus decreasing the diffusive flow, and it increases the bubble point as the largest pores become blocked. Also, the effective thickness of the membrane increases as material accretes on its surface. These effects have implications with respect to the integrity-test values and their correlation to bacterial retention. Certainly, porosity reduction and the increase in thickness depend on the feed stream and the properties of the particles (gel or solid) removed from it.

Filter loading influences diffusive-flow and bubble-point values, although not to the same degree and not in the same sequence according to published studies. Postfiltration integrity testing evaluates filters that have been subject to an unknown level of particulate loading; therefore the influence of the particulate loading on the integrity-test results is also unknown. It is reasonable to assume, however, that as particles are arrested by the membrane, the porosity of the membrane decreases and the bubble point increases. This assumption has been confirmed experimentally (8). Testing under different conditions or with different membrane types and configurations could produce different results, however.

Extensive validation testing using multiple lots of product representative of normal production is necessary to determine the potential effects of filter loading on the postfiltration integrity-test values. In any case, the precise effect of the filter loading on the postfiltration integrity test cannot be known with certainty; therefore, it is not possible to ensure that filter loading has not masked a defect that initially may have been present in the filter.

Recommendations and conclusion

Regulatory agencies differ in their positions regarding the need for prefiltration integrity testing of membrane filters used to sterilize liquid pharmaceutical and biopharmaceutical products. Annex 1 of the EC Guide to Good Manufacturing Practice specifies integrity testing of the sterilized filter before and after use. FDA's 2004 Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing suggests that integrity testing can be performed before processing and that integrity testing should be routinely performed post-use to detect leaks or defects that may have occurred during the filtration process. The FDA guidance does not take into account potential changes in the validated prefiltration integrity-test values as a result of filter loading.

Because the validation studies correlating bacterial retention with integrity-test results use prefiltration integrity-test values, albeit with a safety factor, the only reliable way to ensure that the filters used in production are equivalent to those used to establish the integrity-test specification is to perform a prefiltration integrity test. The postfiltration integrity test then serves its intended function: to ensure the filter has not been damaged during the sterilization or filtration process.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here